Tofacitinib an alternative treatment for refractory cutaneous dermatomyositis
Tofacitinib, an oral Janus kinase (JAK)-1/3 inhibitor approved for treating rheumatoid arthritis, was beneficial in treating cutaneous dermatomyositis in three patients who had failed traditional therapies, according to a report published in JAMA Dermatology.
Dr. Drew J.B. Kurtzman of the...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Arthritis | Dermatology | Dermatomyositis | Rheumatoid Arthritis | Rheumatology | Skin